Catalog No.
DHC90731
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PRO131921
Clone ID
PRO131921
Immunotherapy in indolent Non-Hodgkin's Lymphoma., PMID:35663281
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter., PMID:32827580
Future therapies for pemphigus vulgaris: Rituximab and beyond., PMID:26792592
Oncological emergencies: increased intracranial pressure in solid tumours' metastatic brain disease., PMID:25016783
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics., PMID:24928323
Novel CD20 monoclonal antibodies for lymphoma therapy., PMID:23057966
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies., PMID:21090841
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy., PMID:20712081
The future of CD20 monoclonal antibody therapy in B-cell malignancies., PMID:20367564
CD20-targeted therapy: the next generation of antibodies., PMID:20350667
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma., PMID:20425465
For research use only. Not for human or drug use.
